B7-H3 / CD276 Antibody ( FITC )

B7-H3 / CD276 Antibody Datasheet

B7-H3 / CD276 Antibody Product Information

• Immunogen: Recombinant Human B7-H3 / CD276 protein (Catalog#11188-H08H)
• Reagents: FITC-conjugated mouse monoclonal antibody
• Clone ID: 06
• Ig Type: Mouse IgG2b
• Concentration: 10 μl/Test, 0.1 mg/ml
• Formulation: Aqueous solution containing 0.5% BSA and 0.09% sodium azide
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human B7-H3 / CD276 (rh B7-H3 / CD276; Catalog#11188-H08H; Q5ZPR3-1; Met 1-Thr 461) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

B7-H3 / CD276 Antibody Usage Guide

• Specificity: Human B7-H3 / CD276
• No cross-reactivity in WB and ELISA with
  

  Human cell lysate (293 cell line)

• Flow Cytometry:
  

  Flow cytometric analysis of anti-B7H3 (CD276) reactivity on PC-3 cells.

  Flow cytometry was performed on a BD FACSCalibur flow cytometry system

  Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

• Storage: This antibody is stable for 12 months from date of receipt when stored at 2℃- 8℃. Protected from prolonged exposure to light. Do not freeze !
  Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

B7-H3 / CD276 Antibody Background

B7-H3 is one of the most recently identified members of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T-cell response. B7 family molecules, which are expressed on antigen-presenting cells and display extracellular regions containing immunoglobulin (Ig) variable (V)- and constant (C)-like domains, are known to modulate T cell receptor (TCR)-mediated T cell activation by providing co-signals that are either stimulatory or inhibitory. B7-H3 provides a stimulatory signal to T cells. However, recent studies suggest a negative regulatory role for B7-H3 in T cell responses. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3 is a negative regulator that preferentially affects T (H)1 responses. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. Recently, B7-H3 expression has also been found in a variety of different human cancers, including prostate cancer, clear cell renal cell carcinoma (ccRCC), non-small-cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, ovarian cancer, colorectal cancer (CRC) and urothelial cell carcinoma. B7-H3 was expressed in some human cancers and correlated with poor outcome of cancer patients.

References

1. Loos M. et al., 2010, Clin Dev Immunol. 2010: 683875.
2. Nagashima O. et al., 2008, J Immunol. 181 (6): 4062-71.
3. Suh WK. et al., 2003, Nat Immunol. 4 (9): 899-906.
4. Waschbisch A. et al., 2008, Arthritis Rheum. 58 (11): 3600-8.
5. Sun J. et al., 2010, Cancer Immunol Immunother. 59 (8): 1163-71.